Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Stanford University
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01078350
First received: February 26, 2010
Last updated: July 7, 2016
Last verified: July 2016
  Purpose
This study is designed to collect tissue samples that may aid in the treatment and learning about various oncology diagnosis.

Condition Intervention
Lymphoma
Hodgkin Disease
Procedure: tumor tissue aspiration
Procedure: phlebotomy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Further analysis [ Time Frame: at collection time ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
tissues sample

Estimated Enrollment: 100
Study Start Date: May 2004
Estimated Study Completion Date: May 2099
Estimated Primary Completion Date: May 2099 (Final data collection date for primary outcome measure)
Detailed Description:
The purpose of this study is to provide a mechanism to obtain tissue specimens to be used for experimental studies before the exact histologic diagnosis is known.
  Eligibility

Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects who are having a tissue procedure done as part of their standard oncology work-up will be eligible to be consented on this study.
Criteria

Inclusion Criteria:

  • Subjects who are having a tissue procedure done as part of their standard oncology work-up will be eligible to be consented on this study.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01078350

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Peds Hem Onc CRAs       hemonccras@lists.stanford.edu   
Principal Investigator: Neyssa Marina         
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Dr. Neyssa Marina Stanford University
  More Information

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01078350     History of Changes
Other Study ID Numbers: BANKPEDSTS0001  80003  SU-11052007-794 
Study First Received: February 26, 2010
Last Updated: July 7, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Stanford University:
Lymphoma
Hodgkin Disease

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on December 09, 2016